Clinical Trial Update: Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing safety and efficacy of iguratimod for chronic graft-versus-host disease (cGVHD).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Iguratimod (iguratimod)

Snippet

Sponsor: Xuzhou Medical University | Conditions: cGVHD | Phase 3 | Status: UNKNOWN